
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4104398/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MRI is useful to suggest and exclude malignancy in mucinous cystic neoplasms of the pancreas. European Radiology, 2022, 32, 1297-1307.	4.5	4
2	Colonic involvement in acute mesenteric ischemia: prevalence, risk factors, and outcomes. European Radiology, 2022, 32, 2813-2823.	4.5	6
3	Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. Journal of Hepatology, 2022, 76, 343-352.	3.7	30
4	MR imaging features and long-term evolution of benign focal liver lesions in Budd-Chiari syndrome and Fontan-associated liver disease. Diagnostic and Interventional Imaging, 2022, 103, 111-120.	3.2	6
5	Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. Journal of Hepatology, 2022, 76, 420-434.	3.7	41
6	Segmental Arterial Mediolysis. Radiology, 2022, 302, 515-515.	7.3	1
7	Performance of non-invasive biomarkers compared with invasive methods for risk prediction of posthepatectomy liver failure in hepatocellular carcinoma. British Journal of Surgery, 2022, 109, 455-463.	0.3	7
8	Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease. Hepatology International, 2022, 16, 509-522.	4.2	16
9	Transarterial Radioembolization Versus Atezolizumab–Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life. Advances in Therapy, 2022, , 1.	2.9	6
10	Endovascular revascularization of acute arterial mesenteric ischemia: report of a 3-year experience from an intestinal stroke center unit. European Radiology, 2022, 32, 5606-5615.	4.5	12
11	Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria. Hepatology, 2022, 76, 1318-1328.	7.3	10
12	Differentiation of hepatocellular adenoma by subtype and hepatocellular carcinoma in non-cirrhotic liver by fractal analysis of perfusion MRI. Insights Into Imaging, 2022, 13, 81.	3.4	5
13	Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Cancers, 2022, 14, 2634.	3.7	0
14	Outcome of liver cancer patients with SARSâ€CoVâ€2 infection: An International, Multicentre, Cohort Study. Liver International, 2022, 42, 1891-1901.	3.9	11
15	Laparoscopic-assisted liver transplantation: A realistic perspective. American Journal of Transplantation, 2022, 22, 3069-3077.	4.7	3
16	Monocrotaline Toxicity Alters the Function of Hepatocyte Membrane Transporters in Rats. International Journal of Molecular Sciences, 2022, 23, 7928.	4.1	2
17	The diagnostic performance of a simulated "short―gadoxetic acid-enhanced MRI protocol is similar to that of a conventional protocol for the detection of colorectal liver metastases. European Radiology, 2021, 31, 2451-2460.	4.5	10
18	Computed Tomography-Derived Liver Surface Nodularity and Sarcopenia as Prognostic Factors in Patients with Resectable Metabolic Syndrome-Related Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 405-416.	1.5	10

#	Article	IF	CITATIONS
19	Imaging of disseminated actinomycosis. Diagnostic and Interventional Imaging, 2021, 102, 399-401.	3.2	0
20	Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area. JHEP Reports, 2021, 3, 100199.	4.9	55
21	Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma. European Radiology, 2021, 31, 3267-3275.	4.5	9
22	Efficacy of Chest CT for COVID-19 Pneumonia Diagnosis in France. Radiology, 2021, 298, E81-E87.	7.3	57
23	Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France. CardioVascular and Interventional Radiology, 2021, 44, 36-49.	2.0	15
24	Quantification of Pancreas Surface Lobularity on CT: A Feasibility Study in the Normal Pancreas. Korean Journal of Radiology, 2021, 22, 1300.	3.4	5
25	Imaging as predictor of clinical response to teduglutide in adult patients with short bowel syndrome with chronic intestinal failure. American Journal of Clinical Nutrition, 2021, 113, 1343-1350.	4.7	5
26	Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma. Clinical Therapeutics, 2021, 43, 1201-1212.	2.5	4
27	Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101731.	1.5	2
28	Enhancing capsule in hepatocellular carcinoma: intra-individual comparison between CT and MRI with extracellular contrast agent. Diagnostic and Interventional Imaging, 2021, 102, 735-742.	3.2	13
29	Long-term outcomes following resection of hepatocellular adenomas with small foci of malignant transformation or malignant adenomas. JHEP Reports, 2021, 3, 100326.	4.9	7
30	Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial). European Journal of Cancer, 2021, 154, 46-56.	2.8	10
31	The SVD beamformer with diverging waves: a proof-of-concept for fast aberration correction. Physics in Medicine and Biology, 2021, 66, 18LT01.	3.0	5
32	Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS. JHEP Reports, 2021, 3, 100380.	4.9	29
33	Gallbladder Volvulus. Radiology, 2021, 301, 43-43.	7.3	3
34	Pathologic, Molecular, and Prognostic Radiologic Features of Hepatocellular Carcinoma. Radiographics, 2021, 41, 1611-1631.	3.3	32
35	Steatosis Alters the Activity of Hepatocyte Membrane Transporters in Obese Rats. Cells, 2021, 10, 2733.	4.1	2
36	Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 305-313.	2.8	16

#	Article	IF	CITATIONS
37	Clinical impact of a new cone beam CT angiography respiratory motion artifact reduction algorithm during hepatic intra-arterial interventions. European Radiology, 2020, 30, 163-174.	4.5	11
38	Gender gap in articles published in European Radiology and CardioVascular and Interventional Radiology: evolution between 2002 and 2016. European Radiology, 2020, 30, 1011-1019.	4.5	25
39	Hepatic angiomyolipoma: an international multicenter analysis on diagnosis, management and outcome. Hpb, 2020, 22, 622-629.	0.3	19
40	Women in radiology: gender diversity is not a metric—it is a tool for excellence. European Radiology, 2020, 30, 1644-1652.	4.5	56
41	Quantification of hepatic steatosis with ultrasound: promising role of attenuation imaging coefficient in a biopsy-proven cohort. European Radiology, 2020, 30, 2293-2301.	4.5	65
42	Performance of liver surface nodularity quantification for the diagnosis of portal hypertension in patients with cirrhosis: comparison between MRI with hepatobiliary phase sequences and CT. Abdominal Radiology, 2020, 45, 365-372.	2.1	16
43	CT and MR perfusion techniques to assess diffuse liver disease. Abdominal Radiology, 2020, 45, 3496-3506.	2.1	13
44	Extension of COVID-19 pulmonary parenchyma lesions based on real-life visual assessment on initial chest CT is an independent predictor of poor patient outcome. Infectious Diseases, 2020, 52, 838-840.	2.8	6
45	Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma. JHEP Reports, 2020, 2, 100147.	4.9	15
46	A nomogram to predict the risk of unfavourable outcome in COVID-19: a retrospective cohort of 279 hospitalized patients in Paris area. Annals of Medicine, 2020, 52, 367-375.	3.8	28
47	CT-Based Radiomics Analysis to Predict Malignancy in Patients with Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Cancers, 2020, 12, 3089.	3.7	32
48	NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with ⁹⁰ Y Resin Microspheres Versus Sorafenib in Advanced Hepatocellular Carcinoma. Journal of Nuclear Medicine, 2020, 61, 1736-1742.	5.0	27
49	Contrast-Enhanced CT for the Diagnosis of Acute Mesenteric Ischemia. American Journal of Roentgenology, 2020, 215, 29-38.	2.2	30
50	Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome. JHEP Reports, 2020, 2, 100097.	4.9	11
51	New insights in the management of Hepatocellular Adenoma. Liver International, 2020, 40, 1529-1537.	3.9	18
52	Evaluation of liver tumour response by imaging. JHEP Reports, 2020, 2, 100100.	4.9	33
53	Factors Associated with Tumor Progression After Percutaneous Ablation of Hepatocellular Carcinoma: Comparison Between Monopolar Radiofrequency and Microwaves. Results of a Propensity Score Matching Analysis. CardioVascular and Interventional Radiology, 2020, 43, 1608-1618.	2.0	8
54	Long-term Evolution of Hepatocellular Adenomas at MRI Follow-up. Radiology, 2020, 295, 361-372.	7.3	17

#	Article	IF	CITATIONS
55	Relationship of Tumor Radiation–absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with ⁹⁰ Y in the SARAH Study. Radiology, 2020, 296, 673-684.	7.3	117
56	Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases. Hepatology International, 2020, 14, 437-453.	4.2	68
57	Imaging of liver tumours: What's new?. Liver International, 2020, 40, 154-159.	3.9	1
58	Hereditary hemorrhagic telangiectasia and liver involvement. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 426-432.	1.5	5
59	Budd-Chiari syndrome. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 420-425.	1.5	9
60	CT-based liver surface nodularity for the detection of clinically significant portal hypertension: defining measurement quality criteria. Abdominal Radiology, 2020, 45, 2755-2763.	2.1	11
61	Women in focus: advice from the front lines on how to enable well-being and build resilience. Insights Into Imaging, 2020, 11, 55.	3.4	2
62	Colorectal liver metastases: radiopathological correlation. Insights Into Imaging, 2020, 11, 99.	3.4	18
63	Impact of Liver Diseases on HeartÂandÂLungs. JACC: Cardiovascular Imaging, 2019, 12, 2071-2075.	5.3	2
64	Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellularâ€cholangiocarcinoma. Liver International, 2019, 39, 2386-2396.	3.9	32
65	Liver CT perfusion: which is the relevant delay that reduces radiation dose and maintains diagnostic accuracy?. European Radiology, 2019, 29, 6550-6558.	4.5	7
66	Targeted and non-targeted liver biopsies carry the same risk of complication. European Radiology, 2019, 29, 5772-5783.	4.5	12
67	Rare Solid Tumor of the Exocrine Pancreas: A Pictorial Review. Seminars in Ultrasound, CT and MRI, 2019, 40, 483-499.	1.5	2
68	lso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping. European Radiology, 2019, 29, 3791-3801.	4.5	19
69	Hepatocellular Carcinoma: Current Imaging Modalities for Diagnosis and Prognosis. Digestive Diseases and Sciences, 2019, 64, 934-950.	2.3	46
70	Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response. Cancer Imaging, 2019, 19, 75.	2.8	29
71	Endovascular Treatment of Arterial Complications After Liver Transplantation: Long-Term Follow-Up Evaluated on Doppler Ultrasound and Magnetic Resonance Cholangiopancreatography. CardioVascular and Interventional Radiology, 2019, 42, 381-388.	2.0	11
72	Portal vein variants associated with right hepatectomy: An analysis of abdominal CT angiography with 3D reconstruction. Clinical Anatomy, 2019, 32, 328-336.	2.7	8

#	Article	IF	CITATIONS
73	Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari syndrome. Journal of Hepatology, 2019, 70, 1123-1132.	3.7	37
74	Gender discrepancy in research activities during radiology residency. Insights Into Imaging, 2019, 10, 125.	3.4	18
75	Hepatocellular carcinoma surveillance: Eastern and Western perspectives. Ultrasonography, 2019, 38, 191-199.	2.3	13
76	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 2018, 69, 182-236.	3.7	6,153
77	Hepatocellular carcinoma surveillance with ultrasound—cost-effectiveness, high-risk populations, uptake. British Journal of Radiology, 2018, 91, 20170436.	2.2	7
78	Benign and malignant hepatocellular lesions in patients with vascular liver diseases. Abdominal Radiology, 2018, 43, 1968-1977.	2.1	44
79	Peritoneal and pleural fluids may appear hyperintense on hepatobiliary phase using hepatobiliary MR contrast agents. European Radiology, 2018, 28, 3020-3031.	4.5	10
80	Uncommon evolutions and complications of common benign liver lesions. Abdominal Radiology, 2018, 43, 2075-2096.	2.1	12
81	Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3†cm. Journal of Hepatology, 2018, 68, 715-723.	3.7	83
82	Macrotrabecularâ€massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. Hepatology, 2018, 68, 103-112.	7.3	159
83	Diagnosis of Budd–Chiari syndrome. Abdominal Radiology, 2018, 43, 1896-1907.	2.1	35
84	Focal Nodular Hyperplasia After Treatment With Oxaliplatin: A Multiinstitutional Series of Cases Diagnosed at MRI. American Journal of Roentgenology, 2018, 210, 775-779.	2.2	31
85	Polycystic liver disease: Hepatic venous outflow obstruction lesions of the noncystic parenchyma have major consequences. Hepatology, 2018, 68, 652-662.	7.3	25
86	Quantification of Liver Surface Nodularity at CT: Utility for Detection of Portal Hypertension. Radiology, 2018, 289, 698-707.	7.3	45
87	Inter-reader agreement of CT features of acute mesenteric ischemia. European Journal of Radiology, 2018, 105, 87-95.	2.6	31
88	Reply to "Oxaliplatin-Induced Liver Changes on Gadoxetate Disodium–Enhanced Liver MRI― American Journal of Roentgenology, 2018, 211, W134-W134.	2.2	0
89	Is magnetic resonance imaging useful for the management of patients with rectal villous adenoma? A study of 45 consecutive patients treated by transanal endoscopic microsurgery. International Journal of Colorectal Disease, 2018, 33, 1695-1701.	2.2	5
90	Predictors of treatment response following aspiration sclerotherapy of hepatic cysts: an international pooled analysis of individual patient data. European Radiology, 2017, 27, 741-748.	4.5	12

#	Article	IF	CITATIONS
91	Differences in healthâ€related quality of life between European and Asian patients with hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e304-e311.	1.1	9
92	Neuroendocrine liver metastases: Vascular patterns on triple-phase MDCT are indicative of primary tumour location. European Journal of Radiology, 2017, 89, 156-162.	2.6	38
93	Letter to the Editor re: Should fat in the radiofrequency ablation zone of hepatocellular adenomas raise suspicion for residual tumour?. European Radiology, 2017, 27, 2235-2236.	4.5	0
94	Molecular Classification of Hepatocellular Adenoma AssociatesÂWith Risk Factors, Bleeding, and Malignant Transformation. Gastroenterology, 2017, 152, 880-894.e6.	1.3	290
95	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncology, The, 2017, 18, 1624-1636.	10.7	595
96	Liver transarterial embolizations in metastatic neuroendocrine tumors. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 459-471.	5.7	38
97	Molecular classification of hepatocellular adenoma in clinical practice. Journal of Hepatology, 2017, 67, 1074-1083.	3.7	119
98	A Rare Cause of Pancreatitis. Gastroenterology, 2017, 153, 655-656.	1.3	1
99	Long-term Outcome and Analysis of Dysfunction of Transjugular Intrahepatic Portosystemic Shunt Placement in Chronic Primary Budd-Chiari Syndrome. Radiology, 2017, 283, 280-292.	7.3	54
100	Risks factors for severe pain after selective liver transarterial chemoembolization. Liver International, 2017, 37, 583-591.	3.9	21
101	Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging. European Radiology, 2017, 27, 1748-1759.	4.5	80
102	VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials. JMIR Research Protocols, 2017, 6, e17.	1.0	11
103	Functional imaging in liver tumours. Journal of Hepatology, 2016, 65, 1017-1030.	3.7	45
104	Optimal visualization of focal nodular hyperplasia: quantitative and qualitative evaluation of single and multiphasic arterial phase acquisition at 1.5ÂT MR imaging. Abdominal Radiology, 2016, 41, 990-1000.	2.1	4
105	Cannabinoid receptor activation in the juvenile rat brain results in rapid biomechanical alterations: Neurovascular mechanism as a putative confounding factor. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 954-964.	4.3	12
106	Safety of supramesocolic surgery in patients with portal cavernoma without portal vein decompression. Large single centre experience. Hpb, 2016, 18, 623-629.	0.3	5
107	Sequential transarterial chemoembolization and portal vein embolization before resection is a valid oncological strategy for unilobar hepatocellular carcinoma regardless of the tumor burden. Hpb, 2016, 18, 684-690.	0.3	35
108	Imaging review of hepatocellular carcinoma after thermal ablation: The good, the bad, and the ugly. Journal of Magnetic Resonance Imaging, 2016, 44, 1070-1090.	3.4	19

#	Article	IF	CITATIONS
109	Imaging of Hepatic Focal Nodular Hyperplasia: Pictorial Review and Diagnostic Strategy. Seminars in Ultrasound, CT and MRI, 2016, 37, 511-524.	1.5	32
110	Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation. Liver Transplantation, 2016, 22, 1491-1500.	2.4	31
111	Avoiding Pitfalls in the Interpretation of Gadoxetic Acid–Enhanced Magnetic Resonance Imaging. Seminars in Ultrasound, CT and MRI, 2016, 37, 561-572.	1.5	12
112	Development of Collateral Pathways in Tumor Obstruction of Confluence of the Hepatic Veins: Neither Fortuitous nor Innocuous. Journal of the American College of Surgeons, 2016, 223, 595-601.	0.5	4
113	Indication of Percutaneous Microwave Ablation for the Treatment of Hepatic Adenomas: Squaring the Circle. Journal of Vascular and Interventional Radiology, 2016, 27, 932-933.	0.5	2
114	Response: Transient liver modifications associated with abdominal sepsis are various and underestimated. European Radiology, 2016, 26, 4327-4328.	4.5	0
115	Multiparametric magnetic resonance imaging in patients with chronic liver disease: are we there yet?. Liver International, 2016, 36, 631-633.	3.9	0
116	Acute extrahepatic infectious or inflammatory diseases are a cause of transient mosaic pattern on CT and MR imaging related to sinusoidal dilatation of the liver. European Radiology, 2016, 26, 3094-3101.	4.5	19
117	A meta-analysis of diffusion-weighted and gadoxetic acid-enhanced MR imaging for the detection of liver metastases. European Radiology, 2016, 26, 4595-4615.	4.5	126
118	Transient excess of liver fat detected by magnetic resonance imaging in women with acute fatty liver of pregnancy. American Journal of Obstetrics and Gynecology, 2016, 214, 127-129.	1.3	22
119	Endovascular management of delayed post-pancreatectomy haemorrhage. European Radiology, 2016, 26, 3456-3465.	4.5	27
120	Cone-Beam CT Angiography for Determination of Tumor-Feeding Vessels During Chemoembolization of Liver Tumors: Comparison of Conventional and Dedicated-Software Analysis. Journal of Vascular and Interventional Radiology, 2016, 27, 32-38.	0.5	28
121	Pitfalls in Liver Imaging. Radiology, 2016, 278, 34-51.	7.3	43
122	Insights into the diagnosis of hepatocellular carcinomas with hepatobiliary MRI. Journal of Hepatology, 2016, 64, 708-716.	3.7	37
123	Liver steatosis assessed by preoperative MRI: An independent risk factor for severe complications after major hepatic resection. Surgery, 2016, 159, 1050-1057.	1.9	14
124	Cone Beam Computed Tomography (CBCT) in the Field of Interventional Oncology of the Liver. CardioVascular and Interventional Radiology, 2016, 39, 8-20.	2.0	63
125	Hepatic Proliferation and Angiogenesis Markers Are Increased after Portal Deprivation in Rats: A Study of Molecular, Histological and Radiological Changes. PLoS ONE, 2015, 10, e0125493.	2.5	10
126	Assessment of liver ablation using cone beam computed tomography. World Journal of Gastroenterology, 2015, 21, 517.	3.3	24

#	Article	IF	CITATIONS
127	Hepatocellular Carcinoma With Osseous Metaplasia and Bone Marrow Elements. Clinical Gastroenterology and Hepatology, 2015, 13, e26-e27.	4.4	2
128	Quality of life changes in patients undergoing treatment for hepatocellular carcinoma. Quality of Life Research, 2015, 24, 2499-2506.	3.1	26
129	Combined Transhepatic Portal Venous and Transarterial Treatment of Superior Mesenteric Arteriovenous Fistula in a Patient with Cirrhosis. Journal of Vascular and Interventional Radiology, 2015, 26, 601-603.	0.5	4
130	TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma. Liver International, 2015, 35, 2466-2473.	3.9	24
131	Is magnetic resonance imaging of hepatic hemangioma any different in liver fibrosis and cirrhosis compared to normal liver?. European Journal of Radiology, 2015, 84, 816-822.	2.6	15
132	Shear-wave Elastography for the Noninvasive Diagnosis of Focal Liver Lesions: It Always Starts with the Clinical Context. Radiology, 2015, 276, 928-929.	7.3	0
133	Viscoelastic Parameters for Quantifying Liver Fibrosis: Three-Dimensional Multifrequency MR Elastography Study on Thin Liver Rat Slices. PLoS ONE, 2014, 9, e94679.	2.5	20
134	Clinical studies in hepatocellular carcinoma. Future Oncology, 2014, 10, 13-16.	2.4	2
135	Hepatic capsular retraction: spectrum of diagnosis at MRI. Acta Radiologica Short Reports, 2014, 3, 204798161454566.	0.7	4
136	Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Trials, 2014, 15, 474.	1.6	38
137	Hepatic hemangiomas: Factors associated with T2 shine-through effect on diffusion-weighted MR sequences. European Journal of Radiology, 2014, 83, 468-478.	2.6	36
138	Re: "Radiofrequency Ablation of Hepatic Cysts: Evaluation of Therapeutic Efficacy― Journal of Vascular and Interventional Radiology, 2014, 25, 808.	0.5	0
139	Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) – A phase II non-randomised trial. European Journal of Cancer, 2014, 50, 3098-3106.	2.8	69
140	The Liver Halo Sign after Tumor Ablation. Journal of Vascular and Interventional Radiology, 2014, 25, 1641-1643.	0.5	1
141	Diagnosis and management of solid benign liver lesions. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 737-749.	17.8	89
142	Hepatocellular carcinoma: Diagnostic criteria by imaging techniques. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 795-812.	2.4	37
143	Imaging of benign hepatocellular lesions: Current concepts and recent updates. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 681-688.	1.5	48
144	Hepatocellular adenomas: Accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology, 2011, 53, 1182-1191.	7.3	180

#	Article	IF	CITATIONS
145	Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities. Hepatology, 2011, 54, 1987-1997.	7.3	309
146	A Single-Center Surgical Experience of 122 Patients With Single and Multiple Hepatocellular Adenomas. Gastroenterology, 2009, 137, 1698-1705.	1.3	347
147	Sequential Arterial and Portal Vein Embolization in Patients with Cirrhosis and Hepatocellular Carcinoma: The Hospital Beaujon Experience. Seminars in Interventional Radiology, 2008, 25, 155-161.	0.8	13
148	Focal nodular hyperplasia. European Journal of Radiology, 2006, 58, 236-245.	2.6	132
149	Atrophy-Hypertrophy Complex in Patients with Cavernous Transformation of the Portal Vein: CT Evaluation. Radiology, 2006, 241, 149-155.	7.3	83
150	Tumour detection in the liver: role of multidetector-row CT. European Radiology, Supplement, 2005, 15, d85-d88.	1.4	2
151	Prevalence of Hepatic Hemangioma in Patients with Focal Nodular Hyperplasia: MR Imaging Analysis. Radiology, 2003, 229, 75-79.	7.3	123
152	Peritoneal carcinomatosis in patients with digestive endocrine tumors. Cancer, 1996, 78, 1686-1692.	4.1	54
153	Correlation of MR changes with doppler US measurements of blood flow in exercising normal muscle. Journal of Magnetic Resonance Imaging, 1992, 2, 645-652.	3.4	11
154	Comparison between ultrasonographic signs and the degree of portal hypertension in patients with cirrhosis. Gastrointestinal Radiology, 1990, 15, 218-222.	0.4	81